Navigation Links
MU researchers studying model to learn why certain cancers become resistant to drugs
Date:10/2/2007

COLUMBIA, Mo. Resistance to chemotherapy treatments can be the worst news a cancer patient ever receives. A pair of researchers at the University of Missouri-Columbia is working steadfastly to learn why some tumors eventually build a tolerance to the common chemotherapy drug cisplatin, in hopes of identifying the particular genes that can be manipulated to make treatment as effective as possible.

In a paper published in the latest edition of Proceedings of the National Academy of Sciences (PNAS), Hannah and Stephen Alexander, professors of biological sciences in MUs College of Arts and Science, in collaboration with Gad Shaulsky and Adam Kuspa, professors at the Baylor School of Medicine, demonstrate that a model organism called Dictyostelium discoideum is useful for studying mechanisms of cisplatin drug sensitivity. Dictyostelium discoideum cells share many genes and biochemistry with human cells there are more than 30,000 genes in one human cell compared with 15,000 in Dictyostelium discoideum which simplifies the process of isolating and studying particular genes. The current study identified 400 genes that have the potential for use in improving cisplatin therapy.

The basic issue is that many types of cancer are treated with cisplatin, Stephen Alexander said. In some cases its the best drug, and in some cases its the only drug. Nevertheless, lots of cancers are either resistant to it or become resistant during treatment. Theres a lot of work being done in developing new drugs as cancer therapies, but not many of them have come on the market yet. Since cisplatin is effective and has already been approved, why not try to make it better"

During more than eight years of research, the Alexanders have examined why tumors become resistant to cisplatin and what, if any, biochemical pathways can be used to improve the drugs efficiency. They identified genes for sphingolipid metabolism as key to whether a tumor cell lives or dies after treatment with cisplatin. The current collaboration with the Baylor team has greatly expanded these studies.

Shaulsky and Kuspa have developed microarray technologies to determine the patterns of gene expression in Dictyostelium discoideum and detect the effects of treatments. Together, the teams of researchers embarked to find the global response to cisplatin and how mutants in sphingolipid metabolism resistant to cisplatin affected the response. The study established that the cause of resistance is not simply that cells do not take up the drug or that the drug is neutralized, but that a specific set of genes responds uniquely to the treatment. Finding ways to use those genes to increase sensitivity to cisplatin could lead to more effective therapy.

We used genetics to find genes that are involved, and we discovered several completely novel pathways that no one had ever thought was involved with this, Stephen Alexander said. Ultimately, were looking for a way to make cisplatin more effective, and the idea is to find out whats going on in the cell that determines whether cells are sensitive or not, and to boost some pathway to make it better.


'/>"/>

Contact: Kevin Carlson
CarlsonKE@missouri.edu
573-882-3346
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers identify the early makers of Neonatal Sepsis
4. OHSU Researchers Announce New Discovery
5. Researchers Identify Gene Connected To Bipolar Disorder
6. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
7. Researchers trick Alzheimers Enzyme
8. Researchers find new HIV hiding place
9. Gene researchers make Malaria-resistant mosquito
10. New Hair in 15 Days Could Now Be A Possibility Say Researchers
11. Researchers developed world’s smallest toothbrus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: